Fexofenadine Inhibits TNF Signaling Through Targeting to Cytosolic Phospholipase A2 and is Therapeutic Against Inflammatory Arthritis

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2019 Jul 15

PMID 31302596

Citations 21

Authors

Ronghan Liu

Yuehong Chen

Wenyu Fu

Shuya Wang

Yazhou Cui

Xiangli Zhao

Zi-Ning Lei

Aubryanna Hettinghouse

Jody Liu

Chao Wang

Chen Zhang

Yufei Bi

Guozhi Xiao

Zhe-Sheng Chen

Chuan-Ju Liu

Affiliations

Soon will be listed here.

Abstract

Objective: Tumour necrosis factor alpha (TNF-α) signalling plays a central role in the pathogenesis of various autoimmune diseases, particularly inflammatory arthritis. This study aimed to repurpose clinically approved drugs as potential inhibitors of TNF-α signalling in treatment of inflammatory arthritis.

Methods: In vitro and in vivo screening of an Food and Drug Administration (FDA)-approved drug library; in vitro and in vivo assays for examining the blockade of TNF actions by fexofenadine: assays for defining the anti-inflammatory activity of fexofenadine using TNF-α transgenic (TNF-tg) mice and collagen-induced arthritis in DBA/1 mice. Identification and characterisation of the binding of fexofenadine to cytosolic phospholipase A2 (cPLA2) using drug affinity responsive target stability assay, proteomics, cellular thermal shift assay, information field dynamics and molecular dynamics; various assays for examining fexofenadine inhibition of cPLA2 as well as the dependence of fexofenadine's anti-TNF activity on cPLA2.

Results: Serial screenings of a library composed of FDA-approved drugs led to the identification of fexofenadine as an inhibitor of TNF-α signalling. Fexofenadine potently inhibited TNF/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ĸB) signalling in vitro and in vivo, and ameliorated disease symptoms in inflammatory arthritis models. cPLA2 was isolated as a novel target of fexofenadine. Fexofenadine blocked TNF-stimulated cPLA2 activity and arachidonic acid production through binding to catalytic domain 2 of cPLA2 and inhibition of its phosphorylation on Ser-505. Further, deletion of cPLA2 abolished fexofenadine's anti-TNF activity.

Conclusion: Collectively, these findings not only provide new insights into the understanding of fexofenadine action and underlying mechanisms but also provide new therapeutic interventions for various TNF-α and cPLA2-associated pathologies and conditions, particularly inflammatory rheumatic diseases.

Citing Articles

Emodin mitigates rheumatoid arthritis through direct binding to TNF-α.

Lu D, Tian X, Cao T, Chen S, Liu C, Zheng L Front Pharmacol. 2025; 16:1520281.

PMID: 40078278 PMC: 11896996. DOI: 10.3389/fphar.2025.1520281.

Targeting TRPC channels for control of arthritis-induced bone erosion.

Ray S, McCall J, Tian J, Jeon J, Douglas A, Tyler K Sci Adv. 2025; 11(3):eabm9843.

PMID: 39813349 PMC: 11734723. DOI: 10.1126/sciadv.abm9843.

Fexofenadine As Successful Adjunctive Treatment of Rheumatoid Arthritis and Trochanteric Bursitis: A Case Report.

Yos E, Hines E, Thomas M, Angeles C, Chetrit D Cureus. 2024; 16(9):e69401.

PMID: 39403668 PMC: 11472682. DOI: 10.7759/cureus.69401.

10-hydroxy-2-decenoic acid prevents osteoarthritis by targeting aspartyl β hydroxylase and inhibiting chondrocyte senescence in male mice preclinically.

Geng N, Fan M, Kuang B, Zhang F, Xian M, Deng L Nat Commun. 2024; 15(1):7712.

PMID: 39231947 PMC: 11375154. DOI: 10.1038/s41467-024-51746-3.

Dietary pyruvate targets cytosolic phospholipase A2 to mitigate inflammation and obesity in mice.

Hasan S, Ghani N, Zhao X, Good J, Huang A, Wrona H Protein Cell. 2024; 15(9):661-685.

PMID: 38512816 PMC: 11365557. DOI: 10.1093/procel/pwae014.

References

Marusic S, Leach M, Pelker J, Azoitei M, Uozumi N, Cui J . Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis. J Exp Med. 2005; 202(6):841-51. PMC: 2212947. DOI: 10.1084/jem.20050665. View

Ruocco M, Karin M . IKK{beta} as a target for treatment of inflammation induced bone loss. Ann Rheum Dis. 2005; 64 Suppl 4:iv81-5. PMC: 1766902. DOI: 10.1136/ard.2005.042721. View

Sanchez-Mejia R, Newman J, Toh S, Yu G, Zhou Y, Halabisky B . Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci. 2008; 11(11):1311-8. PMC: 2597064. DOI: 10.1038/nn.2213. View

Clark J, Lin L, Kriz R, Ramesha C, Sultzman L, Lin A . A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell. 1991; 65(6):1043-51. DOI: 10.1016/0092-8674(91)90556-e. View

Surolia I, Pirnie S, Chellappa V, Taylor K, Cariappa A, Moya J . Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature. 2010; 466(7303):243-7. PMC: 2900412. DOI: 10.1038/nature09115. View

Patel M, Singh J, Niknami M, Kurek C, Yao M, Lu S . Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer. Clin Cancer Res. 2008; 14(24):8070-9. PMC: 2605658. DOI: 10.1158/1078-0432.CCR-08-0566. View

Tang W, Lu Y, Tian Q, Zhang Y, Guo F, Liu G . The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science. 2011; 332(6028):478-84. PMC: 3104397. DOI: 10.1126/science.1199214. View

Kokotou M, Limnios D, Nikolaou A, Psarra A, Kokotos G . Inhibitors of phospholipase A and their therapeutic potential: an update on patents (2012-2016). Expert Opin Ther Pat. 2016; 27(2):217-225. DOI: 10.1080/13543776.2017.1246540. View

Simanshu D, Kamlekar R, Wijesinghe D, Zou X, Zhai X, Mishra S . Non-vesicular trafficking by a ceramide-1-phosphate transfer protein regulates eicosanoids. Nature. 2013; 500(7463):463-7. PMC: 3951269. DOI: 10.1038/nature12332. View

10.

Shimamura T, Shiroishi M, Weyand S, Tsujimoto H, Winter G, Katritch V . Structure of the human histamine H1 receptor complex with doxepin. Nature. 2011; 475(7354):65-70. PMC: 3131495. DOI: 10.1038/nature10236. View

11.

Netterwald J . TNF-blocker triple approval. Nat Biotechnol. 2009; 27(6):495. DOI: 10.1038/nbt0609-495. View

12.

Dennis E, Norris P . Eicosanoid storm in infection and inflammation. Nat Rev Immunol. 2015; 15(8):511-23. PMC: 4606863. DOI: 10.1038/nri3859. View

13.

Bonventre J, Huang Z, Taheri M, OLeary E, Li E, Moskowitz M . Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature. 1997; 390(6660):622-5. DOI: 10.1038/37635. View

14.

Phan H, Moeller M, Nahata M . Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Drugs. 2009; 69(18):2541-76. DOI: 10.2165/9884960-000000000-00000. View

15.

Chong C, Sullivan Jr D . New uses for old drugs. Nature. 2007; 448(7154):645-6. DOI: 10.1038/448645a. View

16.

Farooqui A, Ong W, Horrocks L . Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev. 2006; 58(3):591-620. DOI: 10.1124/pr.58.3.7. View

17.

Brenner D, Blaser H, Mak T . Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. 2015; 15(6):362-74. DOI: 10.1038/nri3834. View

18.

Leurs R, Vischer H, Wijtmans M, de Esch I . En route to new blockbuster anti-histamines: surveying the offspring of the expanding histamine receptor family. Trends Pharmacol Sci. 2011; 32(4):250-7. DOI: 10.1016/j.tips.2011.02.004. View

19.

Lin L, Wartmann M, Lin A, Knopf J, Seth A, Davis R . cPLA2 is phosphorylated and activated by MAP kinase. Cell. 1993; 72(2):269-78. DOI: 10.1016/0092-8674(93)90666-e. View

20.

Palladino M, Bahjat F, Theodorakis E, Moldawer L . Anti-TNF-alpha therapies: the next generation. Nat Rev Drug Discov. 2003; 2(9):736-46. DOI: 10.1038/nrd1175. View